


Surface Plasmon Resonance for Immunoassays

Sadagopan Krishnan

Chem 395

Instructor: Prof. Rusling



Outline

- **Introduction**
- **Understanding the Basics**
- **SPR- Instrumental components**
- **Applications in Immunoassays**
- **Advantages / Disadvantages**
- **Summary**

What is SPR?

- **Surface sensitive optical detection method—interactions between biomolecules**
 - protein-protein**
 - protein-ligand**
 - protein-DNA**
 - protein-membrane**
- **Phenomenon that occurs when light is reflected off thin metal films.**
- **Light energy interacts with the delocalized e⁻s in the metal surface – reduced reflected light intensity.**
- **Identification and Quantification (association, dissociation and equilibrium constants, and energetics) of these interactions.**

Understanding the Basics of SPR

Refraction of Light





Figure 1

Refractive Index (RI) = Ratio of speed of light in vacuum to that in a denser medium

Principle of SPR operation



- **Tunneling of Electromagnetic field into interior side of surface (forming evanescent wave) and reflection .**
- **Photon energy absorbed by electrons on the surface when their momentum are equal (resonance condition).**
- **Oscillating electrons on the surface at resonance called “plasmons” hence the name “surface plasmon resonance” and the angle θ_{SPR} .**

Evanescent wave and θ_{SPR}




Figure 1. Mechanism of the SP excitation.

- At θ_{SPR} , the reflected light intensity decreases and this difference is measured in SPR.
- When a molecule B interacts with immobilized A, shift in θ_{SPR} (or λ_{SPR}) can be observed due to change in refractive index.

Refractive index change and permittivity

- Refractive index change is related to the permittivity of the medium and adsorbed layer as below.

$$n_{prism} \cdot \sin(\theta) = \sqrt{\frac{\epsilon_m \cdot \epsilon_{ad\ layer}}{\epsilon_m + \epsilon_{ad\ layer}}}$$

wave vector of radiation

$$\epsilon_m = 1 - \frac{\lambda^2 \lambda_c}{\lambda_c (\lambda + i\lambda_c)}$$

λ = wavelength of resonance
 λ_c = wavelength of plasmon
Hence, ϵ_m depends on λ

Two ways: either keep λ constant and vary θ or vice-versa and observe the change in the light intensity.⁷

Summary-1


We have understood some basic concepts in SPR and interaction of molecules related to the SPR response.

-Let us know about immunoassays (remember Jim's lecture on Immunosensors).

Immunoassays

- **A biochemical test-measures levels of a particular molecule in biological samples- e.g. serum, urine – uses antibody reaction to its antigen (specific binding).**
- **Clinically important in identifying pathogens. e.g. Prostate specific antigen, highly specific biomarker for prostate cancer.**
- **Monoclonal Antibody – binds only to one site of a particular antigen, hence specific and accurate.**
- **Polyclonal antibody – heterogeneous mixture of antibodies against different epitopes of the antigen.**

SPR for Immunoassays




L - light source, P - prism, S – sensor surface, D– photodiode array, F- flow cell, Light intensity drop at times t_1 and t_2 .

t_1 = before binding the antigen;

t_2 = resonance position after binding the antigen.

SPR Sensogram



Kinetics- Analysis of Experimental SPR Curves



Fit the experimental curve into various reaction models* and get the kinetic parameters from the best fit.

- (1) Pseudo first-order reaction model
- (2) Mass transport limitation model
- (3) Inhomogeneous ligand model
- (4) Inhomogeneous analyte model

Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users

Phinikoula S. Katsamba ^a, Iva Navratilova ^a, Maria Calderon-Cacia ^b, Linsey Fan ^c, Kevin Thornton ^c, Mingde Zhu ^c, Tim Vanden Bos ^d, Carla Forte ^d, Della Friend ^d, Ite Laird-Offringa ^e, Gisele Tavares, John Whatley, Ergang Shi ^f, Angela Widom ^g, Kevin C. Lindquist ^h, Scott Klakamp ⁱ, Andrew Drake ⁱ, David Bohmann ^j, Marina Roell ^j, Larry Rose ^j, Jill Dorocke ^k, Bruce Roth ^l, Béatrice Luginbühl ^m, David G. Myszka ^{a,*}

^a Center for Biomolecular Interaction Analysis, School of Medicine, University of Utah, Salt Lake City, UT 84132, USA

^b Chiron Corp., Emeryville, CA 94608, USA

^c Bio-Rad Laboratories, Hercules, CA 94547, USA

^d Amgen, Inc., Seattle, WA 98101, USA

^e University of Southern California, Los Angeles, CA 90033, USA

^f Regeneron Pharmaceutical, Tarrytown, NY 10591, USA

^g Wyeth, Cambridge, MA 02140, USA

^h Biacore Inc., Piscataway, NJ 08854, USA

ⁱ Abgenix Inc., Fremont, CA 94555, USA

^j Xoma (US) LLC, Berkeley, CA 94710, USA


^k Eli Lilly and Co., Indianapolis, IN 46285, USA

^l Myriad Pharmaceuticals, Salt Lake City, UT 84108, USA

^m Department of Biochemistry, Universitaet Zürich, Zürich, Switzerland

Katsamba et al. Analytical Biochemistry 352 (2006) 208–221


Prostate specific Antigen (PSA) binding to monoclonal antibody (mAb)




Outline of the paper

- **PSA- 30 kDa protein - routinely used marker in the diagnosis of prostate cancer.**
- **In this study, 22 participants measured the binding of PSA to a mAb by SPR.**
- **mAb-immobilized on carboxymethyl dextran surface-amine-coupling chemistry using EDC and NHS.**
- **Three different densities of mAb immobilized-varying contact times and dilution.**
- **[PSA] used in 2.5-600 nM range for k_a calculation.**
- **[PSA] of 600 nM for k_d experiment.**
- **Global fitting of data using 1:1 interaction model.**

PSA/mAb – association and dissociation kinetics




➤ Association phase of the PSA/mAb interaction over a PSA concentration range is reproducible.



➤ Dissociation phase of PSA/mAb interaction at [PSA]=600nM is reproducible. Spikes are artifacts arising from the filling of syringes.


Analysis: 1:1 interaction model ($A+B=AB$), Scrubber software




Black lines = experimental (increasing concentrations of PSA)

Orange lines = model fit


Distribution of kinetic rates & equilibrium binding constants among 22 users



$$k_a = (4.1 \pm 0.6) \times 10^4 M^{-1} s^{-1}$$



$$k_d = (4.5 \pm 0.6) \times 10^{-5} s^{-1}$$



Equilibrium Binding constant,

$$K_D = \frac{k_d}{k_a} = 1.1 \pm 0.2 nM$$

Advantages

- **Real time analysis & Label free technique – No need for radioactive, fluorescent or any other labelling.**
- **The Change in SPR signal - specific to the binding event - no need for purified sample – antigen in extracts can be used.**
- **Highly sensitive (RI changes $<10^{-5}$ with time resolution of few seconds) and simple construction.**

Disadvantages

- **Mass transport can affect kinetic analysis.**
- **Any artifactual RI change other than from the interaction can also give signal.**
- **One of the interacting molecules should be immobilized on the surface.**
- **Thickness of the metal film (thin film is preferred).**

Summary-2

- **Surface plasmon resonance has been shown to be a powerful technique in studying real-time kinetics of immunoassays.**
- **Its advantages over other techniques can be understood.**

Acknowledgements

- **Prof. Rusling**
- **Prof. Kumar**
- **Chem 395 class**

Thank You

Questions?

Thickness and Surface concentration from SPR

$$d = (I_d / 2)(R / R_{\max}) = (I_d / 2) \left\{ R / [m(\eta_a - \eta_s)] \right\}$$

d = thickness of the adsorbed layer

I_d = decay length of evanescent wave

R = change in bulk index of refraction

m = slope of R vs $\Delta\eta$ plot

η_a = refractive index of adsorbed layer

η_s = refractive index of bulk solution.

$$N \text{ (in molecules/cm}^3\text{)} = \frac{\theta \text{ (in molecules/cm}^2\text{)}}{d \text{ (in cm)}}$$

Adsorption kinetics- anti-transferrin binding to staphylococcal protein A




Fig. 2. The kinetic adsorption curve of anti-transferrin on the SPA monolayer in the directly immune assays.

Differential rate equations of various reaction models*

Pseudo-first-order reaction model

$$d[B]/dt = -(k_a \cdot [A] \cdot [B] - k_d \cdot [AB])$$

$$d[AB]/dt = (k_a \cdot [A] \cdot [B] - k_d \cdot [AB])$$

$$R = [AB] + RI$$

Mass transport limitation model

$$d[A_{sur}]/dt = k_i \cdot ([A_{bulk}] - [A_{sur}]) - (k_a \cdot [A_{sur}] \cdot [B] - k_d \cdot [AB])$$

$$d[B]/dt = -(k_a \cdot [A_{sur}] \cdot [B] - k_d \cdot [AB])$$

$$d[AB]/dt = (k_a \cdot [A_{sur}] \cdot [B] - k_d \cdot [AB])$$

$$R = [AB] + RI$$

Inhomogeneous ligand model

$$d[B]/dt = -(k_{a1} \cdot [A] \cdot [B] - k_{d1} \cdot [AB])$$

$$d[B']]/dt = -(k_{a2} \cdot [A] \cdot [B'] - k_{d2} \cdot [AB'])$$

$$d[AB]/dt = (k_{a1} \cdot [A] \cdot [B] - k_{d1} \cdot [AB])$$

$$d[AB']]/dt = (k_{a2} \cdot [A] \cdot [B'] - k_{d2} \cdot [AB'])$$

$$R = [AB] + [AB'] + RI$$

Inhomogeneous analyte model

$$d[B]/dt = -(k_{a1} \cdot [A] \cdot MW \cdot [B] - k_{d1} \cdot [AB]) / MW - (2 \cdot k_{a2} \cdot [A_2] \cdot MW \cdot [B] - k_{d2} \cdot [A_2B]) / (2 \cdot MW)$$

$$d[AB]/dt = (k_{a1} \cdot [A] \cdot MW \cdot [B] - k_{d1} \cdot [AB])$$

$$d[A_2B]/dt = (2 \cdot k_{a2} \cdot [A_2] \cdot MW \cdot [B] - k_{d2} \cdot [A_2B])$$

$$R = [AB] + [A_2B] + RI$$

*J. Luo *et al.* *J. Biochem.* 130, 553-559 (2001).